March 20, 2025 03:41 PM EDTUpdated 1 hour ago

Akero exec calls FDA's accelerated approval guidance for MASH drugs 'bizarre'

Max Bayer

Pharma Reporter

NEW YORK — Akero Therapeutics may not have adequate data for accelerated approval of its MASH drug, despite showing it may reverse cirrhosis in patients with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Akero exec calls FDA's accelerated approval guidance for MASH drugs 'bizarre'

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking ‘the big next step’ after AlphaFold 3

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

Updated: FDA approves Alnylam’s Amvuttra in ATTR-CM, kicking off competition with Pfizer, BridgeBio

Johnson & Johnson earmarks $55B to boost US capacity

CDC vaccine meeting, delayed earlier this year, is rescheduled

Novo Nordisk says new early R&D structure will ‘future-proof’ its business

Akero ex­ec calls FDA's ac­cel­er­at­ed ap­proval guid­ance for MASH drugs 'bizarre'

Pharma Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Akero exec calls FDA's accelerated approval guidance for MASH drugs 'bizarre'